ストックスクリーナーアプリを入手
1.59
1.85%
-0.03
前日終値:
$1.62
開ける：
$1.63
24時間の取引高:
541.51K
Relative Volume:
0.61
時価総額：
$171.96M
収益：
$27.08M
当期純損益:
$-37.00M
株価収益率:
-3.0577
EPS:
-0.52
ネットキャッシュフロー:
$-18.46M
1週間 パフォーマンス:
-0.63%
1か月 パフォーマンス:
-18.46%
6か月 パフォーマンス:
+35.90%
1年 パフォーマンス:
+28.23%
1日の値動き範囲:
$1.58
$1.665
1週間の範囲:
$1.565
$1.775
52週間の値動き範囲:
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
ACRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.59 | 171.96M | 27.08M | -37.00M | -18.46M | -0.52 |
|
TMO
Thermo Fisher Scientific Inc
|
500.16 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.85 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
415.87 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
116.69 | 33.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
177.39 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-18 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-11-19 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 開始されました | Evercore ISI | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-10-06 | 開始されました | BTIG Research | Buy |
| 2021-07-23 | 再開されました | Jefferies | Buy |
| 2021-06-15 | 開始されました | Piper Sandler | Overweight |
| 2021-04-21 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 開始されました | SVB Leerink | Outperform |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2018-02-09 | 開始されました | Guggenheim | Buy |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 開始されました | Leerink Partners | Outperform |
| 2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-06-10 | 開始されました | Guggenheim | Buy |
| 2015-11-02 | 開始されました | Citigroup | Buy |
| 2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
HighTower Advisors LLC Has $652,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases - Investing.com India
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN
Aclaris Therapeutics ATM - Leerink Partners
Cantor Fitzgerald Has Weak Forecast for ACRS FY2025 Earnings - Defense World
Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by Analysts at Cantor Fitzgerald - Defense World
Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 - MSN
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion By Investing.com - Investing.com South Africa
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion - Investing.com
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MSN
Common Warts Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Scotiabank Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Scotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Aclaris stock target at $15 with new rating - Investing.com
Scotiabank sets Aclaris stock target at $15 with new rating By Investing.com - Investing.com UK
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St
Cantor Fitzgerald Predicts ACRS FY2025 Earnings - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00 - Defense World
Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88% - Simply Wall St
Cantor Fitzgerald Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-Buy - Defense World
Aclaris Therapeutics plans $300M mixed shelf offering - MSN
Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewswire
Will Aclaris Therapeutics Reveal New Pipeline Updates at March Healthcare Conferences? - StockTitan
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Yahoo Finance
JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Aclaris Therapeutics Inc (NASDAQ: ACRS): Hidden Gems In A Time Of Volatility - Stocks Register
Hair Loss Treatment Market Hits New High | Major Giants Follica, Theradome, Histogen, Aclaris Therapeutics - Newstrail
Q1 Earnings Forecast for ACRS Issued By Leerink Partnrs - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results - MarketBeat
Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aclaris Therapeutics Reports 2024 Financial Results - TipRanks
Aclaris: Q4 Earnings Snapshot - CT Insider
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates - MSN
Aclaris Therapeutics Inc earnings missed by $0.72, revenue topped estimates - Investing.com
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
Aclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c) - TipRanks
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan - MSN
Aclaris Therapeutics Inc (ACRS) Becoming More Attractive for Investors - Knox Daily
Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Tuesday - Defense World
Aclaris Therapeutics (ACRS) Expected to Announce Earnings on Tuesday - MarketBeat
Common Warts Market to Expand Significantly by 2034, States - openPR
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
Aclaris Therapeutics Inc (ACRS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
0.80%
0.71%
大文字化:
|
ボリューム (24 時間):